Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for severe bleeding disorder: major trial tests preventive drug

NCT ID NCT06998524

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a medication called emicizumab can safely prevent bleeding episodes in people with a severe, rare form of von Willebrand disease (Type 3). It will compare emicizumab given as a regular preventive treatment against the current standard care, which is treating bleeds as they happen. The goal is to see if this new approach can help people have fewer bleeds and improve their quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AOU Careggi

    RECRUITING

    Florence, Tuscany, 50134, Italy

  • Charlotte Maxeke Johannesburg Academic Hospital

    RECRUITING

    Johannesburg, 2193, South Africa

  • Erasmus MC

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz

    RECRUITING

    Duisburg, 47051, Germany

  • Great Ormond Street Hospital

    RECRUITING

    London, WC1N 3JH, United Kingdom

  • Groupe Hospitalier Necker Enfants Malades

    RECRUITING

    Paris, 75015, France

  • Hopital Claude Huriez - CHU Lille

    RECRUITING

    Lille, 59037, France

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • Hospital Universitario la Paz

    RECRUITING

    Madrid, 28046, Spain

  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin

    RECRUITING

    Frankfurt/M., 60590, Germany

  • IPS SURA Industriales Medellín

    RECRUITING

    Medellín, Colombia

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Lombardy, 20122, Italy

  • Instytut Hematologii i Transfuzjologii

    RECRUITING

    Warsaw, 02-776, Poland

  • Kurume University Hospital

    RECRUITING

    Fukuoka, 830-0011, Japan

  • Manchester Royal Infirmary

    RECRUITING

    Manchester, M13 9WL, United Kingdom

  • McGill University Health Center

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Nagoya University Hospital

    RECRUITING

    Nagoya, 466-8560, Japan

  • Sahlgrenska Universitetssjukhuset

    RECRUITING

    Gothenburg, S-413 45, Sweden

  • St Thomas' Hospital

    RECRUITING

    London, SE1 7EH, United Kingdom

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • UC Davis

    RECRUITING

    Sacramento, California, 95817, United States

  • UZ Leuven Gasthuisberg

    RECRUITING

    Leuven, 3000, Belgium

  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia

    RECRUITING

    Rome, Lazio, 00161, Italy

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Minnesota Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Universitätsklinikum Bonn

    RECRUITING

    Bonn, 53127, Germany

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

VON WILLEBRAND DISEASE, TYPE 3